N N dimethyltryptamine - PharmaTher
Alternative Names: DMA - PharmaTher; DMT - PharmaTher; N, N-dimethyltryptamine - PharmaTherLatest Information Update: 20 Jul 2023
At a glance
- Originator PharmaTher
- Class Antidepressants; Antipsychotics; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
- Mechanism of Action Neuron modulators; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mental disorders
Most Recent Events
- 18 Jul 2023 Positive research data from a study with N,N-dimethyltryptamine PharmaPatch released by PharmaTher
- 01 Feb 2023 PharmaTher and PharmaDrug agree to co-develop N N dimethyltryptamine
- 11 Jan 2022 Preclinical trials in Mental disorders in Canada (Transdermal) as of January 2022 (PharmaTher pipeline, January 2022)